{"id":"https://openalex.org/W4388399613","doi":"https://doi.org/10.1111/bcp.15955","title":"Model\u2010informed dose selection for an investigational human epidermal growth factor receptor 2 antibody\u2013drug conjugate FS\u20101502 in patients with human epidermal growth factor receptor 2\u2010expressing advanced malignant solid tumours","display_name":"Model\u2010informed dose selection for an investigational human epidermal growth factor receptor 2 antibody\u2013drug conjugate FS\u20101502 in patients with human epidermal growth factor receptor 2\u2010expressing advanced malignant solid tumours","publication_year":2023,"publication_date":"2023-11-06","ids":{"openalex":"https://openalex.org/W4388399613","doi":"https://doi.org/10.1111/bcp.15955","pmid":"https://pubmed.ncbi.nlm.nih.gov/37926561"},"language":"en","primary_location":{"id":"doi:10.1111/bcp.15955","doi":"https://doi.org/10.1111/bcp.15955","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1111/bcp.15955","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.15955","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.15955","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111905317","display_name":"Yi Sun","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104190","display_name":"Fosun Pharma (China)","ror":"https://ror.org/01kk11s67","country_code":"CN","type":"company","lineage":["https://openalex.org/I4210104190"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yi Sun","raw_affiliation_strings":["Shanghai Fosun Pharmaceutical Development Co., Ltd., Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shanghai Fosun Pharmaceutical Development Co., Ltd., Shanghai, China","institution_ids":["https://openalex.org/I4210104190"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100323145","display_name":"Chao Li","orcid":"https://orcid.org/0000-0002-0112-7535","observed_orcids":["https://orcid.org/0000-0002-0112-7535"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chao Li","raw_affiliation_strings":["Anheart Therapeutics, New York, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anheart Therapeutics, New York, New York, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053519302","display_name":"Xingli Wang","orcid":"https://orcid.org/0000-0003-2785-9707","observed_orcids":["https://orcid.org/0000-0003-2785-9707","https://orcid.org/0009-0005-9880-4641","https://orcid.org/0000-0002-5609-4769"]},"institutions":[{"id":"https://openalex.org/I4210104190","display_name":"Fosun Pharma (China)","ror":"https://ror.org/01kk11s67","country_code":"CN","type":"company","lineage":["https://openalex.org/I4210104190"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xingli Wang","raw_affiliation_strings":["Shanghai Fosun Pharmaceutical Development Co., Ltd., Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shanghai Fosun Pharmaceutical Development Co., Ltd., Shanghai, China","institution_ids":["https://openalex.org/I4210104190"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100942297","display_name":"Yi Zheng","orcid":"https://orcid.org/0009-0000-6717-0395","observed_orcids":["https://orcid.org/0009-0000-6717-0395"]},"institutions":[{"id":"https://openalex.org/I4210104190","display_name":"Fosun Pharma (China)","ror":"https://ror.org/01kk11s67","country_code":"CN","type":"company","lineage":["https://openalex.org/I4210104190"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yi Zheng","raw_affiliation_strings":["Shanghai Fosun Pharmaceutical Development Co., Ltd., Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shanghai Fosun Pharmaceutical Development Co., Ltd., Shanghai, China","institution_ids":["https://openalex.org/I4210104190"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101177299","display_name":"Zhuli Wu","orcid":"https://orcid.org/0009-0001-3898-3255","observed_orcids":["https://orcid.org/0009-0001-3898-3255","https://orcid.org/0009-0000-8151-502X"]},"institutions":[{"id":"https://openalex.org/I4210104190","display_name":"Fosun Pharma (China)","ror":"https://ror.org/01kk11s67","country_code":"CN","type":"company","lineage":["https://openalex.org/I4210104190"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zhuli Wu","raw_affiliation_strings":["Shanghai Fosun Pharmaceutical Development Co., Ltd., Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shanghai Fosun Pharmaceutical Development Co., Ltd., Shanghai, China","institution_ids":["https://openalex.org/I4210104190"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026189241","display_name":"Ai\u2010Min Hui","orcid":"https://orcid.org/0000-0002-3688-1570","observed_orcids":["https://orcid.org/0000-0002-3688-1570"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ai\u2010Min Hui","raw_affiliation_strings":["EnCureGen Pharma, Guangzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EnCureGen Pharma, Guangzhou, China","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5011739456","display_name":"Lei Diao","orcid":"https://orcid.org/0000-0002-0979-8827","observed_orcids":["https://orcid.org/0000-0002-0979-8827"]},"institutions":[{"id":"https://openalex.org/I4210104190","display_name":"Fosun Pharma (China)","ror":"https://ror.org/01kk11s67","country_code":"CN","type":"company","lineage":["https://openalex.org/I4210104190"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Lei Diao","raw_affiliation_strings":["Shanghai Fosun Pharmaceutical Development Co., Ltd., Shanghai, China"],"raw_orcid":"https://orcid.org/0000-0002-0979-8827","affiliations":[{"raw_affiliation_string":"Shanghai Fosun Pharmaceutical Development Co., Ltd., Shanghai, China","institution_ids":["https://openalex.org/I4210104190"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5011739456"],"corresponding_institution_ids":["https://openalex.org/I4210104190"],"apc_list":{"value":4330,"currency":"USD","value_usd":4330},"apc_paid":null,"fwci":1.6705,"has_fulltext":true,"cited_by_count":6,"citation_normalized_percentile":{"value":0.81268385,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"90","issue":"4","first_page":"1115","last_page":"1129"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.3312999904155731,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.3312999904155731,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.27149999141693115,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.11509999632835388,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-antibody-drug-conjugate","display_name":"HER2 antibody-drug conjugate","score":0.9150000214576721},{"id":"https://openalex.org/keywords/monomethyl-auristatin-f","display_name":"monomethyl auristatin F","score":0.906000018119812},{"id":"https://openalex.org/keywords/population-pharmacokinetic-model","display_name":"population pharmacokinetic model","score":0.8220000267028809},{"id":"https://openalex.org/keywords/exposure-response-analysis","display_name":"exposure-response analysis","score":0.9800000190734863},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.6660000085830688},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.4729999899864197},{"id":"https://openalex.org/keywords/benefit-risk-balance","display_name":"benefit-risk balance","score":0.6740000247955322},{"id":"https://openalex.org/keywords/weight-based-dosing","display_name":"weight-based dosing","score":0.9440000057220459},{"id":"https://openalex.org/keywords/chinese-patients","display_name":"Chinese patients","score":0.5109999775886536},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.7390000224113464}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7650433778762817},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6317393779754639},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5737719535827637},{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.5649132132530212},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.487167090177536},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47705522179603577},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4561958909034729},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44462528824806213},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.44171321392059326},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4193539619445801},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.4147050976753235},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.38612762093544006},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.16772860288619995},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.1370081603527069},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/bcp.15955","doi":"https://doi.org/10.1111/bcp.15955","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1111/bcp.15955","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.15955","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:37926561","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37926561","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1111/bcp.15955","doi":"https://doi.org/10.1111/bcp.15955","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1111/bcp.15955","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.15955","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9907000064849854}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4388399613.pdf","grobid_xml":"https://content.openalex.org/works/W4388399613.grobid-xml"},"referenced_works_count":34,"referenced_works":["https://openalex.org/W1964321121","https://openalex.org/W2024447346","https://openalex.org/W2038002999","https://openalex.org/W2052768531","https://openalex.org/W2064651476","https://openalex.org/W2071163127","https://openalex.org/W2091666474","https://openalex.org/W2096998441","https://openalex.org/W2100439220","https://openalex.org/W2141607135","https://openalex.org/W2170426247","https://openalex.org/W2171368669","https://openalex.org/W2615174239","https://openalex.org/W2775344839","https://openalex.org/W2789663128","https://openalex.org/W2794114431","https://openalex.org/W2935912602","https://openalex.org/W2947160942","https://openalex.org/W2976352116","https://openalex.org/W2987002164","https://openalex.org/W3047170482","https://openalex.org/W3095210001","https://openalex.org/W3147820834","https://openalex.org/W3149651509","https://openalex.org/W3159031217","https://openalex.org/W3159805754","https://openalex.org/W3163659354","https://openalex.org/W3197359027","https://openalex.org/W3201219318","https://openalex.org/W3204811815","https://openalex.org/W3206805169","https://openalex.org/W4306155108","https://openalex.org/W4322769492","https://openalex.org/W6959427619"],"related_works":["https://openalex.org/W2741996903","https://openalex.org/W4281958646","https://openalex.org/W3167662841","https://openalex.org/W4413397628","https://openalex.org/W4309246758","https://openalex.org/W7131303017","https://openalex.org/W4296622550","https://openalex.org/W7160876618","https://openalex.org/W4400270411","https://openalex.org/W3213940250"],"abstract_inverted_index":{"AIMS:":[0],"The":[1,65,99,138,157],"dose-escalation":[2,94],"phase":[3,62,92,227],"(phase":[4],"Ia":[5],"study)":[6],"of":[7,80,103,159,180,204,231],"a":[8,22,91,146,167,195,201,208],"novel":[9],"human":[10],"epidermal":[11],"growth":[12],"factor":[13],"receptor":[14],"2":[15],"(HER2)":[16],"antibody-drug":[17],"conjugate":[18],"(ADC)":[19],"FS-1502":[20,83,107,139,181],"included":[21],"dose":[23,41,59,96,229],"range":[24],"from":[25,73],"0.1":[26],"to":[27,57,193,200,214],"3.5":[28],"mg/kg":[29,82,184,189,216,233],"in":[30,120,211],"HER2-expressing":[31],"advanced":[32],"malignant":[33],"solid":[34],"tumours.":[35],"However,":[36,187],"the":[37,117,176,225],"defined":[38],"maximum":[39],"tolerated":[40],"was":[42,68,114,136,164,191],"not":[43],"reached.":[44],"This":[45,219],"model-informed":[46],"approach":[47],"integrated":[48],"population":[49],"pharmacokinetic":[50],"(PopPK)":[51],"modelling":[52],"and":[53,95,108,126,153,185,221,235],"exposure-response":[54],"(E-R)":[55],"analysis":[56,174,223],"facilitate":[58],"selection":[60,230],"for":[61,106,116,240],"II.":[63],"METHODS:":[64],"PopPK":[66,134,220],"model":[67,101,135,149,169],"constructed":[69],"using":[70],"PK":[71,140,148,158],"data":[72,141],"109":[74],"Chinese":[75],"patients":[76],"who":[77],"received":[78],"doses":[79],"0.1-3.5":[81],"every":[84],"3":[85],"(Q3W)":[86],"or":[87],"4":[88],"weeks":[89],"during":[90],"I":[93],"expansion":[97],"trial.":[98],"structural":[100],"consisted":[102],"compartment":[104],"models":[105],"unconjugated":[109,160],"monomethyl":[110,161],"auristatin":[111,162],"F.":[112],"E-R":[113,173,222],"explored":[115],"percentage":[118],"change":[119],"tumour":[121],"size,":[122],"overall":[123],"response":[124],"rate":[125],"treatment-related":[127],"adverse":[128],"events.":[129],"RESULTS:":[130],"A":[131],"semi-mechanistic":[132],"2-analyte":[133],"developed.":[137],"were":[142],"best":[143],"described":[144,165],"by":[145,166],"2-compartment":[147,168],"with":[150,170],"parallel":[151],"linear":[152],"nonlinear":[154],"Michaelis-Menten":[155],"eliminations.":[156],"F":[163],"first-order":[171],"elimination.":[172],"supported":[175,236],"clinically":[177],"meaningful":[178],"efficacy":[179,212],"at":[182],"2.3":[183,188,232],"above.":[186],"Q3W":[190,234],"considered":[192],"have":[194],"better":[196],"benefit-risk":[197],"balance":[198],"due":[199],"lower":[202],"incidence":[203],"safety":[205],"events":[206],"without":[207],"significant":[209],"reduction":[210],"compared":[213],"3.0":[215],"Q3W.":[217],"CONCLUSION:":[218],"guided":[224],"recommended":[226],"II":[228],"body":[237],"weight-based":[238],"dosing":[239],"an":[241],"investigational":[242],"HER2":[243],"ADC":[244],"FS-1502.":[245]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-11-06T00:00:00"}